New lung cancer drug kept tumors in check about twice as long as chemo

If you or someone you love is living with lung cancer, here is some good news: a new kind of drug beat chemotherapy at keeping the cancer from growing, and by a wide margin. People with a type of lung cancer called EGFR-mutated, whose tumors had outgrown their usual pills, went about twice as long before the cancer grew on the new drug as they did on chemo.

The drug is called iza-bren. It is the first of its kind to prove itself in a large, final-stage trial, and that gives patients and doctors something new to look forward to.

How the study worked

Researchers at 73 hospitals in China enrolled 432 adults with advanced EGFR lung cancer that had kept growing after a third-generation EGFR pill. Each person was assigned by chance to iza-bren or to standard platinum chemotherapy, and independent reviewers who did not know who got which drug judged whether the cancer had grown. It was a phase 3 randomized trial, published Oct. 26, 2026, in The Lancet. Patients and doctors knew which treatment was given, and the survival results are still preliminary.

What they found

On iza-bren, the cancer stayed in check about twice as long as it did on chemotherapy. In plain terms, the risk of the cancer growing was cut by more than half with the new drug.

Serious side effects were more common with iza-bren, mostly drops in blood counts, which doctors monitor with routine blood tests. The share of people who had to stop treatment because of side effects was the same in both groups, 4 people in each. Lung inflammation linked to treatment showed up in 2 people on iza-bren and none on chemo.

What is iza-bren?

Think of it as a guided delivery truck. An antibody finds the cancer cell and drops off a dose of chemotherapy right there. Iza-bren is the first of this kind of drug to look for two markers at once, called EGFR and HER3, which are both found on these tumors.

Why this is encouraging

When EGFR pills stop working, chemotherapy has long been the usual next step. This trial shows a better option may be on the way, and it is the first phase 3 evidence for a drug built this way. That is real progress for people with this type of lung cancer.

What you can do today

If you or someone close to you has EGFR lung cancer that grew on a pill like osimertinib, write down two questions for the next oncology visit: “Is iza-bren, or a drug like it, an option for me?” and “Is there a clinical trial nearby?” You can also search ClinicalTrials.gov for trial NCT06382116 to see the study details.